Skyhawk Therapeutics公司宣布，其治疗亨廷顿舞蹈症的在研药物SKY-0515在Ⅰ期临床试验A部分和B部分均取得了积极的重要结果，实现了高达72%的亨廷顿蛋白mRNA降低 Skyhawk的SKY-0515在健康志愿者中实现了剂量依赖性的亨廷顿蛋白（HTT）mRNA降低，在多剂量递增研究的最高测试剂量下，HTT mRNA降低了72% SKY-0515在所有测试剂量下总体耐受性良好 鉴于这些积极的重要结果，我们预计将于2024年第三季度对该研究的患者组进行给药，并于明年初启动Ⅱ期研究 波士顿, July 11, 2024 (GLOBE NEWSWIRE) --...

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in the multiple ascending dose study SKY-0515 was...

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets,...